Overview
Euglobulin clot lysis time is a laboratory assay used to assess the overall fibrinolytic activity of plasma. It measures the time taken for a clot formed from the euglobulin fraction of plasma to dissolve. This fraction contains key fibrinolytic components such as fibrinogen, plasminogen, tissue plasminogen activator, and plasminogen activator inhibitor. The test reflects the balance between plasminogen activation and its inhibition and is useful in evaluating bleeding and thrombotic disorders.
Symptoms
ECLT is performed in patients with clinical features suggestive of abnormal fibrinolysis. These may include unexplained bleeding, excessive postoperative bleeding, easy bruising, or symptoms related to thrombosis. Patients with liver disease, disseminated intravascular coagulation, or shock may show altered fibrinolytic activity even before overt clinical manifestations become evident.
Causes
A shortened euglobulin clot lysis time indicates increased fibrinolytic activity, commonly seen in conditions such as disseminated intravascular coagulation, liver disease, malignancy, and primary hyperfibrinolysis.
A prolonged lysis time reflects reduced fibrinolytic activity and may be caused by increased levels of plasminogen activator inhibitors, hypofibrinolysis, or certain thrombotic states. Normal lysis time suggests a balanced fibrinolytic system.
Risk Factors
Risk factors for abnormal ECLT results include underlying liver dysfunction, sepsis, malignancy, major surgery, trauma, and cardiovascular disease. Disorders affecting coagulation factors, chronic inflammatory states, and improper sample handling can also influence fibrinolytic activity. Patients undergoing fibrinolytic therapy require monitoring due to altered clot breakdown dynamics.
Prevention
Although fibrinolytic disorders cannot always be prevented, early assessment using ECLT helps identify imbalances before serious complications occur. Proper management of liver disease, prompt treatment of sepsis, and careful monitoring in high-risk patients reduce adverse outcomes. Accurate sample collection, timely testing, and correlation with other coagulation assays improve diagnostic reliability and support effective clinical management.
